GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zimmer Biomet Holdings Inc (WBO:ZBH) » Definitions » Gross Margin %
中文

Zimmer Biomet Holdings (WBO:ZBH) Gross Margin %

: 72.23% (As of Dec. 2023)
View and export this data going back to 2021. Start your Free Trial

Gross Margin % is calculated as gross profit divided by its revenue. Zimmer Biomet Holdings's Gross Profit for the three months ended in Dec. 2023 was €1,285 Mil. Zimmer Biomet Holdings's Revenue for the three months ended in Dec. 2023 was €1,779 Mil. Therefore, Zimmer Biomet Holdings's Gross Margin % for the quarter that ended in Dec. 2023 was 72.23%.


The historical rank and industry rank for Zimmer Biomet Holdings's Gross Margin % or its related term are showing as below:

WBO:ZBH' s Gross Margin % Range Over the Past 10 Years
Min: 68.94   Med: 71.33   Max: 73.41
Current: 71.82


During the past 13 years, the highest Gross Margin % of Zimmer Biomet Holdings was 73.41%. The lowest was 68.94%. And the median was 71.33%.

WBO:ZBH's Gross Margin % is ranked better than
80.28% of 796 companies
in the Medical Devices & Instruments industry
Industry Median: 53.54 vs WBO:ZBH: 71.82

Zimmer Biomet Holdings had a gross margin of 72.23% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Zimmer Biomet Holdings was 0.00% per year.


Zimmer Biomet Holdings Gross Margin % Historical Data

The historical data trend for Zimmer Biomet Holdings's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zimmer Biomet Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 71.78 70.23 71.29 70.90 71.82

Zimmer Biomet Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 71.49 72.65 71.89 70.43 72.23

Competitive Comparison

For the Medical Devices subindustry, Zimmer Biomet Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zimmer Biomet Holdings Gross Margin % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Zimmer Biomet Holdings's Gross Margin % falls into.



Zimmer Biomet Holdings Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Zimmer Biomet Holdings's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=4869.6 / 6780.481
=(Revenue - Cost of Goods Sold) / Revenue
=(6780.481 - 1910.844) / 6780.481
=71.82 %

Zimmer Biomet Holdings's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=1285 / 1779.072
=(Revenue - Cost of Goods Sold) / Revenue
=(1779.072 - 494.08) / 1779.072
=72.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Zimmer Biomet Holdings  (WBO:ZBH) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Zimmer Biomet Holdings had a gross margin of 72.23% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Zimmer Biomet Holdings Gross Margin % Related Terms

Thank you for viewing the detailed overview of Zimmer Biomet Holdings's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zimmer Biomet Holdings (WBO:ZBH) Business Description

Traded in Other Exchanges
Address
345 East Main Street, Warsaw, IN, USA, 46580
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.